argenx SE
XBRU:ARGX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
326.3
610
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
argenx SE
argenx SE
Cash from Financing Activities
argenx SE
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
argenx SE
XBRU:ARGX
|
Cash from Financing Activities
$1.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Cash from Financing Activities
-$33.2m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Cash from Financing Activities
-€2.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Cash from Financing Activities
-$52.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Cash from Financing Activities
$487.4m
|
CAGR 3-Years
36%
|
CAGR 5-Years
123%
|
CAGR 10-Years
N/A
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Cash from Financing Activities
-$571k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
argenx SE
Glance View
In a landscape where biotechnology companies tirelessly strive to transform scientific insight into therapeutic breakthroughs, argenx SE stands out with its innovative approach to harnessing the body's own immune system to address severe autoimmune diseases. Originating from the biopharmaceutical hubs of Belgium and the Netherlands, argenx was founded in 2008 and has since positioned itself at the forefront of immunology. At the heart of argenx's operations lies its proprietary SIMPLE Antibody™ technology platform, which engineers differentiated therapeutic antibodies. Guided by a deep understanding of disease biology, the company partners closely with academic institutions and leading pharmaceutical companies to transform promising research insights into viable drug candidates. The company's financial sustenance is woven into its intricate business model, which revolves around the development and commercialization of therapeutic antibodies. Their flagship product, efgartigimod, has made significant strides in treating autoimmune diseases such as generalized myasthenia gravis, showcasing the company's ability to translate its scientific endeavors into substantial revenue streams. Argenx generates income primarily through product sales, milestone payments, and royalties from collaborative partnerships. As the company continues to advance its pipeline and expand its global presence, it demonstrates a robust commitment to addressing unmet medical needs while maintaining a keen eye on sustainable growth and profitability. This delicate balance of innovation and financial acumen allows argenx to reinforce its position in the competitive biotech industry.
See Also
What is argenx SE's Cash from Financing Activities?
Cash from Financing Activities
1.3B
USD
Based on the financial report for Jun 30, 2024, argenx SE's Cash from Financing Activities amounts to 1.3B USD.
What is argenx SE's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
25%
Over the last year, the Cash from Financing Activities growth was 1 245%. The average annual Cash from Financing Activities growth rates for argenx SE have been 5% over the past three years , 25% over the past five years .
You don't have any saved screeners yet
